To include your compound in the COVID-19 Resource Center, submit it here.
Phase I safety data for VNRX-5133 enabled VenatoRx Pharmaceuticals Inc. to bring its first institutional investors on board for a $42 million series B round.
Versant Ventures led the tranched round on July
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury